68Ga-RM2 PET/CT for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Gallium 68 RM2 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- 15 Aug 2017 Planned End Date changed from 1 May 2021 to 10 Apr 2021.
- 15 Aug 2017 Planned primary completion date changed from 1 May 2020 to 10 Apr 2020.
- 09 May 2017 Status changed from not yet recruiting to recruiting.